Kiniksa Pharmaceuticals (NASDAQ:KNSA) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Kiniksa Pharmaceuticals (NASDAQ:KNSA) announced its quarterly earnings results on Tuesday. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.06), Zacks reports. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm had revenue of $122.50 million for the quarter, compared to analyst estimates of $123.42 million. During the same period in the previous year, the firm posted $0.35 EPS. The company’s revenue was up 46.9% compared to the same quarter last year.

Kiniksa Pharmaceuticals Price Performance

Shares of NASDAQ:KNSA traded down $0.22 during mid-day trading on Tuesday, reaching $19.42. 69,028 shares of the company were exchanged, compared to its average volume of 533,084. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of -138.67 and a beta of 0.32. Kiniksa Pharmaceuticals has a 1 year low of $16.56 and a 1 year high of $28.15. The firm’s 50-day simple moving average is $19.69 and its 200 day simple moving average is $22.63.

Insider Transactions at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 14,000 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the sale, the chief operating officer now owns 81,975 shares of the company’s stock, valued at approximately $1,604,250.75. This represents a 14.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Mark Ragosa sold 8,969 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total value of $192,385.05. Following the completion of the transaction, the chief financial officer now owns 22,958 shares of the company’s stock, valued at approximately $492,449.10. This trade represents a 28.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,092 shares of company stock worth $745,589 over the last ninety days. Company insiders own 54.57% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on KNSA shares. Wedbush reiterated an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Monday, January 13th. JPMorgan Chase & Co. upped their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Finally, Evercore ISI increased their price objective on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $36.60.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.